Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones

Foghorn Therapeutics Inc.

Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).
Cash, equivalents and marketable securities $243.7M as of Dec 31, 2024, providing cash runway into 2027.
FHD-909 Phase 1 trial enrolling for SMARCA4-mutated cancers (NSCLC primary); preclinical combo data at AACR 2025.
Selective degradation of ARID1B achieved; program update expected in 2025. CBP and EP300 degraders progressing towards IND.
Research and development expenses $94.5M (down from $109.7M); G&A $28.4M (down from $32.4M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.